Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report - Takeaways - MDSpire

Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report

  • By

  • Shicheng Yuan

  • Qun Zhang

  • Yanling Xu

  • Yanfeng Wu

  • Qi Wang

  • July 14, 2026

Share

  • 1

    Pathological transformations during targeted therapy for lung adenocarcinoma can lead to rare subtypes like pulmonary giant cell carcinoma (PGCC).

  • 2

    A 71-year-old male with KRAS G12C mutation developed PGCC after resistance to sotorasib-targeted therapy, confirmed by re-biopsy.

  • 3

    PGCC is characterized by highly atypical tumor cells, rapid growth, strong invasiveness, and poor prognosis, accounting for less than 1% of lung cancers.

  • 4

    The patient's treatment included immunotherapy with camrelizumab and anti-angiogenic therapy after refusing curative options.

  • 5

    Re-biopsy after targeted therapy resistance is crucial for guiding subsequent treatment and diagnosing similar cases.

Original Source(s)

Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report

  • by Shicheng Yuan, Qun Zhang, Yanling Xu, Yanfeng Wu, Qi Wang

  • July 14, 2026

Related Content

What are the beneficial treatment strategies in maintaining T lymphocyte subsets after cancer surgery? A systematic review and network meta-analysis

Machine and deep learning based on magnetic resonance imaging to segment glioblastoma and predict the spread of recurrence: a multicenter retrospective protocol

Case Report: Supraorbital keyhole resection of IDH-mutant grade 3 astrocytoma of the medial orbitofrontal region